Share This Author
Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial
Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials
A New Single-Item Sleep Quality Scale: Results of Psychometric Evaluation in Patients With Chronic Primary Insomnia and Depression.
- E. Snyder, B. Cai, C. Demuro, M. Morrison, W. Ball
- Psychology, MedicineJournal of clinical sleep medicine : JCSM…
- 15 November 2018
The SQS possesses favorable measurement characteristics relative to lengthier or more frequently administered sleep questionnaires in patients with insomnia and depression.
Orexin receptor antagonism for treatment of insomnia
The data suggest that orexin receptor antagonism offers a novel approach to treating insomnia, and Class I evidence that suvorexant improves sleep efficiency over 4 weeks in nonelderly adult patients with primary insomnia.
The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components.
A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide.
An adaptive design for identifying the dose with the best efficacy/tolerability profile with application to a crossover dose‐finding study
This work presents an efficient adaptive dose‐finding strategy that concentrates patient assignments at and around the dose which has the best efficacy/tolerability profile based on a utility function within the setting of a crossover design.
Slow wave sleep enhancement with gaboxadol reduces daytime sleepiness during sleep restriction.
The results of this study are consistent with the hypothesis that enhanced SWS, in this study produced by GBX, reduces physiological sleep tendency and introspective sleepiness and fatigue which typically result from sleep restriction.
Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial
We evaluated the clinical profile of the orexin receptor antagonist suvorexant for treating insomnia in patients with mild‐to‐moderate probable Alzheimer's disease (AD) dementia.